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Toxoplasmosis during pregnancy and infancy
A new approach for Switzerland
Swiss Working Group on congenital Toxoplasmosis
C. Rudin, K. Boubaker, P. A. Raeber, B. Vaudaux, H. C. Bucher, J. G. Garweg, I. Hoesli, C. Kind, P. Hohlfeld
In recent years it has become evident that
screening for and treatment of acute toxoplasmo-
sis during pregnancy may have no measurable im-
pact on vertical transmission and neonatal mor-
bidity and mortality. A broad lack of evidence
with regard to many aspects of congenital toxo-
plasmosis has been recognised in a common Eu-
ropean initiative (EUROTOXO) which reviewed
several thousand published papers on the subject
of toxoplasmosis during pregnancy and child-
hood. It was therefore clear that the strategies
currently implemented in our country would, on
closer inspection, no longer withstand the claim
for evidence-based procedures. The arguments
and call for a change of paradigm in Switzerland
which follow here are the result of a national con-
sensus-finding process involving experts from
various specialities, including gynaecology/ob-
stetrics, paediatrics/neonatology, infectiology,
ophthalmology and laboratory medicine, together
with representatives of the public health authori-
ties.
Introduction
1995 hypotheses
Twelve years ago the Swiss Federal Office 
of Public Health established a multidisciplinary
working group to review the subject of congenital
toxoplasmosis (CT). This extensive effort culmi-
nated in the publication of a supplement to the
Swiss Medical Weekly in 1995 [1]. At that time a
seroprevalence of 46% was determined on the
basis of the results of a study in 9059 women, cor-
responding to 11.8% of the total annual births in
23 out of 26 Swiss cantons. A risk of 1.21% sero-
conversion among seronegative women during
pregnancy was calculated, resulting in an esti-
mated annual figure of 548 neonates with con-
genital toxoplasmosis in our country. As 75% of
such children can be expected to be asymptomatic
at birth, the number of expected pathologies ac-
cording to this calculation would have been 40
cases of chorioretinitis, possibly with impaired vi-
sion, 18 cases with cerebral lesions and 2.7 cases
of perinatal death per year.
The observed burden of congenital
 toxoplasmosis in Switzerland since 1982
In contrast to these predictions, two local
studies have found much lower numbers in recent
years. A national survey conducted in 38 paedi-
atric units of Swiss teaching hospitals between
1995 and 1998 using the Swiss Paediatric Surveil-
lance Unit network found only 15 proven cases of
symptomatic congenital toxoplasmosis, or 4 per
year for this four-year period [2]. In another sur-
vey conducted in the Basel region, more than
64 000 cord blood samples, covering >90% of all
neonates, were collected and studied between
1982 and 1999. Despite increasing maternal age,
seroprevalence for toxoplasmosis among preg-
nant women steadily decreased from 53% (1982–
1985) to 35% (1999). During the same period the
prevalence of CT declined from 0.08% to
0.012%. A total of 28 children with congenital
toxoplasmosis were identified between 1982 and
1999, and only 4 had clinical evidence of disease.
This screening programme identified 1 child with
congenital toxoplasmosis per 2300 live births, or
1.5 per year, far fewer than expected from previ-
ous Swiss estimates (225 : 15 000 [3] and 100 :
15 000 [4]). Clinical disease was observed in 1 of
16 250 neonates or 1 per 4.5 years [5]. A retro-
spective review of data gathered in the Lausanne
region for 12 years between 1995 and 2006 iden-
tified a total number of 37 serologically con-
firmed cases of congenital toxoplasmosis, ac-
counting for one case in 2270 live births, includ-
ing one symptomatic case in infancy per 14 000
live births [6]. 
Strategy and cost-effectiveness
In 1995 it was believed that primary (reduc-
tion of the risk of acquiring toxoplasmosis during
The past decade
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pregnancy) and secondary (treatment of acute
toxoplasmosis during pregnancy) prevention were
the most promising strategies. However, it was
believed that general screening was not cost-ef-
fective for a low incidence country such as
Switzerland. Taking into account the expected
number of cases, testing on a trimestrial basis
would have been the most cost-effective strategy
[7]. It was left to the obstetricians’ judgement to
perform Toxoplasma antibody testing during
pregnancy. According to health insurance (santé-
suisse), women are tested twice on average during
pregnancy.
Prevention
Primary infection with toxoplasmosis during
pregnancy may cause congenital infection and in-
duce mental retardation and blindness in the in-
fant [8, 9]. Primary, secondary and tertiary pre-
vention strategies have been adopted to reduce
the incidence and severity of congenital toxoplas-
mosis. 
Primary prevention
Primary prevention strategies seek to prevent
cases of congenital infection by preventing cases
of maternal infection, involving pre- or early
pregnancy counselling on how to avoid exposure
[10]. 
Secondary prevention
To reduce mother-to-child transmission and
morbidity from congenital toxoplasmosis, some
high-incidence countries such as Austria and
France have chosen a secondary prevention strat-
egy and implemented nationwide programmes to
detect and treat acute Toxoplasma infections dur-
ing pregnancy [11]. In women with evidence of
acute infection spiramycin is usually prescribed
and amniocentesis performed. In the event of
foetal infection, pyrimethamine and sulfonamides
is the treatment of choice and termination is dis-
cussed if foetal abnormalities are detected on ul-
trasound. According to data from 603 confirmed
cases of maternal toxoplasmosis detected by the
French universal screening programme, the over-
all transplacental transmission rate was 29%.
There was a direct correlation between gesta-
tional age and rate of transmission, beginning
with a 2% transmission rate at 8 weeks of gesta-
tion and 6% at 12 weeks, with a sharp linear in-
crease thereafter up to 81% transmission rate at
term. An inverse relationship was found between
the incidence of clinical symptoms and the gesta-
tional age at which maternal seroconversion oc-
curs. At 13 weeks of gestation 61% of children
presented with clinical symptoms, at 26 weeks the
incidence was 25% and at 36 weeks 9% [12].
Thus correct identification of the gestational age
at which seroconversion occurs greatly affects
counselling on the risk of foetal transmission and
morbidity. 
While some studies have reported signifi-
cantly lower transmission rates in children born
to treated mothers [13–17], others have not
[18–21]. In fact, after an extensive review of 2591
papers, including the nine papers which fulfilled
their stringent inclusion criteria [8–15, 25], Wal-
lon and co-workers concluded that current evi-
dence is not sufficient to confirm that treatment
of mothers who seroconvert during pregnancy
prevents foetal infection and improves infant out-
comes [22, 23]. There was no single randomised
comparison, and control groups were mainly his-
torical and therefore in general not directly com-
parable with the treatment groups. Wallon and
co-workers also identified an additional problem
with amniocentesis, as sensitivity and specificity
of PCR diagnosis in amniotic fluid differed widely
between laboratories [24, 25]. 
Tertiary prevention
Finally, tertiary prevention attempts to lessen
the severity of disease sequelae through early de-
tection and treatment of congenital disease. Pro-
ponents of this idea recognise that most congeni-
tal disease is subclinical at birth, but that sequelae
often develop over time [26]. Tertiary prevention
also involves considering termination of preg-
nancy for severely affected foetuses. 
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Eurotoxo [27]
A joint initiative
Given the growing doubts with regard to ef-
fectiveness of primary, secondary and tertiary pro-
phylaxis of congenital toxoplasmosis, a joint ini-
tiative – called EUROTOXO – was started in
2004 by three different partners: the Institute of
Child Health, London, UK, the Staten Serum In-
stitute, Copenhagen, Denmark, and the Institute
of Public Health, Epidemiology and Develop-
ment, Bordeaux, France. 
Stakeholders from Europe, i.e. representatives
of all disciplines involved in research and care for
Toxoplasma patients were brought together to de-
fine the implications of current scientific know-
ledge for a research agenda and policy decisions
on how best to prevent congenital toxoplasmosis
and its consequences. This initiative was launched
to produce a consensus on what is currently
known regarding prevention and management of
congenital toxoplasmosis and its consequences,
and about areas where further research is needed. 
3Methodology
Four panels of international experts engaged
in an intensive review of thousands of published
papers with a view to identifying scientifically
valuable evidence on the burden of toxoplasmosis
in Europe, European national prevention policies,
risk factors for infection during pregnancy, effects
of primary, secondary and tertiary prevention,
available drugs and effectiveness of treatment, and
the reliability, performance and potential risks of
available laboratory and test methods. 
Geographical differences
The seroprevalence of Toxoplasma antibodies
in young women, and the incidence of congenital
infection, vary from one geographical region to
another. In France, for example, the reported
prevalence of congenital disease is 2–3 cases per
1000 live births, a figure 20 times that in the USA,
which is as low as 1:10 000 live births [25]. There
is evidence that the burden of congenital toxo-
plasmosis is lower in Northern Europe than in
the rest of the continent. In cities the prevalence
of toxoplasmosis is lower than in non-metropoli-
tan areas. It increases with age, but decreases with
calendar time and varies according to geographi-
cal origin. Immigrants from Asia or Africa are at
higher risk of infection due to a low seropreva-
lence in these populations. 
Routes of infection
Few studies contribute to the evidence-based
knowledge of routes of Toxoplasma infection in
pregnant women. All findings support the notion
that the oral route is probably the major source of
infection, involving food preparation and con-
sumption. Data from seven European centres in
Belgium, Denmark, France, Italy, Norway, Yu-
goslavia and Switzerland suggest that risk factors
for Toxoplasma infection vary according to local
eating habits, food hygiene and lifestyles. Inade-
quately cooked or raw meat is among the main
risk factors for infection consistently identified in
all centres, including several kinds of meat such as
beef, lamb or game. Pork has only inconsistently
been reported, whereas chicken has recently been
identified as a reservoir. The risk from eating
cured or frozen meat remains unclear. Contact
with soil contributes to a minority of infections.
Owning a pet cat has been reported as a risk fac-
tor for infection in only one study, and does not
play a significant role. 
Effectiveness of primary prevention
A review of the effectiveness of health inter-
vention approaches in pregnant women (primary
prophylaxis) highlights the weakness of the litera-
ture in this area. Several pitfalls were identified,
chiefly including unclear definition of the inter-
vention and lack of control groups. One cohort
study reported a significant reduction in serocon-
version in pregnant women in Belgium, without a
control group. Only two trials have been con-
ducted and reported an increase in knowledge of
routes of transmission and changed behaviour,
but both lack statistical power from which to draw
conclusions on the seroconversion rate. It was
concluded that primary prevention had a poten-
tial effect in preventing congenital toxoplasmosis,
but was still in need of improvement. At present
the recommendations are based on obsolete data.
A variety of policies 
In many respects the outcome of this review is
somewhat sobering. There is a broad lack of
knowledge, probably best reflected by the huge
variety of national public health policies for the
prevention of congenital toxoplasmosis in indi-
vidual European countries. Five countries offi-
cially recommend mandatory prenatal screening,
either by monthly testing (France, Italy) or by
three-monthly testing of susceptible women
(Austria, Lithuania, Slovenia). The National Insti-
tute for Clinical Excellence (NICE) reported in
its guidelines for routine antenatal care that rou-
tine antenatal screening for toxoplasmosis should
not be offered, because the harm from screening
(unnecessary treatment, termination of pregnan-
cies with uninfected or unaffected foetuses, dis-
tress and discomfort of repeated tests and investi-
gations ante- and postnatally) may outweigh the
potential benefits (reduction in cases of CT) [28].
Neonatal screening has been practised in the
USA for a decade [25]. Denmark has officially
recommended and supported a systematic new-
born screening procedure, based on a pilot study
[30], since 1999. However, this programme was
discontinued in 2007 due to lack of evidence that
treatment for toxoplasmosis was effective in pre-
venting later attacks of ocular toxoplasmosis in
children with and without ocular lesions at birth
[29]. In most other European countries there is
no recommendation at all or a formal recommen-
dation not to screen. However, where routine
practice is concerned, several countries conduct
wild prenatal or neonatal screening procedures.
The authors of the Cochrane review identified
3332 papers, none of which met the inclusion cri-
teria for a randomised controlled trial. They con-
cluded that we still do not know whether antena-
tal treatment in women with presumed toxoplas-
mosis reduces mother-to-child transmission, and
they recommend not introducing screening in
countries where treatment is not routine, outside
carefully controlled trials [30].
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Of the many studies on diagnostic methods
used in congenital toxoplasmosis, only a few allow
reliable assessment of the performance of the
 different tests involved in screening or clinical
 diagnosis. 
Screening of seroconversion during 
pregnancy and prenatal diagnosis 
The literature is sparse and lacks good refer-
ence tests. IgM should be the method of choice 
as a first-line diagnosis, with good sensitivity for
all existing methods (reaching 100% with the
ISAGA method) but with a high rate of false po -
sitive tests (some 6% of cases). Introduction of the
Toxoplasma-specific IgG avidity assay with specific
IgM-positive samples collected in the first half of
pregnancy has improved the diagnostic routine
for the detection of T. gondii infection in early
pregnancy. The main achievement is the ability to
rule out infection during pregnancy for many
women who otherwise, on the basis of a positive
specific IgM result and/or a high dye test titre,
would have been identified as having a recent in-
fection. The test is easy to perform in any micro-
biological laboratory, but there is a need for stan-
dardisation of the method and, furthermore,
long-lasting low avidity is a problem in many
pregnant women. In Italy, a country with routine
prenatal screening for toxoplasmosis, repetition
of serology and reinterpretation of the serological
profile (i.e. of all previous results) in 542 mother-
child pairs revealed a false-positive rate of 90% in
results based on IgM-testing, and 12% based on
seroconversion data [31]. 
Risks associated with prenatal diagnosis
In 2005 a prospective randomised trial docu-
mented risks associated with amniocentesis com-
pared with controls [32]. This trial, conducted in
1986, reported a procedure-related rate of foetal
loss of 1.0% (95% CI, 0.3–1.5) for amniocentesis
as compared with a control group. Evidence from
available controlled studies suggests that the ex-
cess pregnancy loss associated with mid-trimester
amniocentesis with concurrent ultrasound guid-
ance is 0.6% (95% CI, 0.3–0.9). Other complica-
tions related to amniocentesis include vaginal
bleeding, leakage of amniotic fluid, infection, and
foetal injury. Some studies have also reported as-
sociations between amniocentesis and neonatal
complications, including neonatal respiratory dis-
tress syndrome and orthopaedic complications.
The latter, however, have usually been associated
with early amniocentesis. In addition, recent stu-
dies have shown conflicting results regarding an
association between amniocentesis and risk of
preterm delivery. The available evidence suggests
no increased risk of preeclampsia, abortion, pla-
centa praevia, dysfunctional labour or late foetal
or infant death associated with amniocentesis. It
has also been suggested that the number of
 additional foetal losses significantly exceeds the
number of prevented cases of congenital toxo-
plasmosis [33].
Psychological consequences of prenatal
screening
Potential psychological consequences of pre-
natal screening and diagnosis of congenital toxo-
plasmosis include parental anxiety due to false
positive results and uncertainties about the prog-
nosis of children with a positive prenatal diagno-
sis. Due to a larger number of false positive
 results, parental anxiety may be particularly im-
portant in screening strategies that include more
frequent serological testing. A positive screening
result, particularly early in pregnancy, may repre-
sent maternal infection prior to conception, in
which case the foetus would be at very low risk for
congenital toxoplasmosis. Hence the outcome of
prenatal screening and diagnosis of congenital
toxoplasmosis is inherently uncertain and may
 entail substantial, and at times unnecessary, anxie -
ty or other negative psychological reactions for
the affected women and their families [32].
Prenatal diagnosis
Only 5 of the 13 studies assessing perfor -
mance of foetal diagnostic tests are of good
methodological quality. PCR technique has in-
creased the accuracy of foetal diagnosis, but its
sensitivity remains below 83%. The specificity of
PCR is almost 100% in reference laboratories,
but much lower rates have been reported in some
laboratories. Recent studies reported that PCR
diagnosis combined with isolation of the parasite
from amniotic fluid in reference laboratories al-
lows accurate diagnosis attaining sensitivity of
91% and specificity of 99%, but takes up to six
weeks.
Postnatal diagnosis in children
Postnatal diagnosis in children born to sero-
converting mothers is based on IgM and IgA
 detection with low performances before one year
of age. The sensitivity of tests for IgM or IgA in
early infancy is limited, ranging from 52% to
66%. The best performances are observed using
ISAGA (IgM) and ELISA (IgA). Alternative
strategies have combined these methods with
tests for specific antibody bands using the ELIFA
technique or immunoblot. Increased sensitivity of
up to 96% within the first three months of life are
reported for combinations of these tests.
Neonatal screening
Only two studies conducted in Denmark and
Switzerland allow appropriate assessment of tests.
Neonatal screening is based on IgM or IgA tests:
the sensitivity of IgM alone is low; combined IgM
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Effectiveness of screening and diagnostic methods (Eurotoxo) [27]
5and IgA testing is the most accurate, with sensitiv-
ity of 94% and specificity of 99.9% [5, 34]. As
shown by Gilbert et al., the detection rate is high-
est until week 2 after birth, but declines there-
after. According to recently published EMSCOT
data, performance of IgM and IgA was poor if the
mother seroconverted in early pregnancy [35]. 
Conclusion regarding diagnostic tests
In conclusion, tests used in both screening
and diagnosis strategies perform inadequately and
lack standardisation and thus reliability. Another
important aspect of secondary prevention relates
to associated risks, the most important being
foetal loss associated with amniocentesis. 
Effectiveness of prenatal treatment
Concerning antiparasitic treatment it must be
stated that there are no pharmacokinetic or phar-
macodynamic studies in children and pregnant
women. Data on serum concentrations of spi-
ramycin suggest that the levels attained are below
the minimal inhibitory concentration for Toxo-
plasma gondii. There are no randomised con-
trolled trials of prenatal treatment, and there is no
clear evidence that prenatal treatment has a clini-
cally important effect on the risk of transmission.
Moreover, the variation in the observed effect of
prenatal treatment on the occurrence of clinical
disease can be explained by biases. 
Effectiveness of postnatal treatment
There is also a lack of evidence on the effect
of postnatal treatment in children, especially for
pyrimethamine/sulfonamides, which account for
a high frequency of adverse events in children.
One single randomised controlled trial from
Brazil shows an effect of cotrimoxazole vs. no
treatment on the recurrence of retinochoroiditis
[36]. 
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Implications of the Eurotoxo findings for the Swiss approach
Old perceptions and habits
In Switzerland wild early pregnancy screening
is performed, an estimated 90% of women being
tested for Toxoplasma-specific antibodies at some
time during pregnancy. Leaflets with primary pre-
vention messages have been distributed in some
regions, but their contents are based on old per-
ceptions rather than evidence regarding most im-
portant transmission routes. Furthermore, there is
no nationwide consensus and the leaflets in ques-
tion are not uniform. Diagnosis of acute toxoplas-
mosis during pregnancy has been based on sero-
conversion, on IgM and IgG testing, and more re-
cently on IgG avidity testing. In many cases, i.e.
based on the presence of IgM and IgG antibodies,
acute toxoplasmosis was a suspected rather than a
proven diagnosis, and many women were treated
on the basis of a questionable interpretation of the
screening results. Treatment of pregnant women
differed between centres, with low dose
pyrimethamine/sulfadoxine treatment more
prominent in the German-speaking regions and
spiramycin treatment followed by prenatal diag-
nosis more often performed in the French-spea-
king regions of the country. Neonates have been
evaluated serologically and clinically at birth.
Clinical evaluation included eye examination and
cerebral ultrasound, and in some centres, in the
case of proven neonatal toxoplasmosis, also tes-
ting of cerebrospinal fluid. Treatment of infants
with proven or suspected congenital toxoplasmo-
sis also differed between centres. In some clinics
children with suspected or asymptomatic conge-
nital toxoplasmosis were prescribed low-dose pro-
phylactic pyrimethamine/sulfadoxine (Fansidar®),
while symptomatic infected children were usually
treated with four-week cycles of alternate spi-
ramycine or pyrimethamine/sulfadiazine and
folinic acid. Treatment was usually given for one
year or until disappearance of passively acquired
maternal antibodies. Infected children usually un-
dergo annual eye examinations until adolescence/
adulthood. 
An accurate estimation of the burden of CT
Switzerland has approximately 73 000 live
births per year. Taking the data from the cord
blood screening in the Basel region into account,
a total of 32 cases of congenital toxoplasmosis
(Basel: 1/2300 live births) and of 4.5 symptomatic
neonates/infants (Basel: 1/16 250 live births) per
year would be expected for the whole country, the
latter figure being exactly the same as observed in
the 1995–98 SPSU survey [2]. Among 39 622
pregnancies between January 1991 and December
1999, the Basel group identified 71 women with
proven or suspected acute toxoplasmosis during
pregnancy [5]. These figures correspond to those
observed in the Lausanne region [6]. Thus, it can
be anticipated that among 73 000 pregnancies 130
women at most will have acute toxoplasmosis du-
ring pregnancy each year in Switzerland. 
Risks versus benefits
Given these low numbers, unsystematic
screening during pregnancy and the limited per-
formance of tests to identify acute toxoplasmosis
during pregnancy with certainty, it seems very
likely that a significant number of women will
 either be missed or treated for a presumed rather
than a real acute infection during pregnancy.
 Further, due to the fact that taking all available
 information into account it is not possible to
demonstrate any effect of treatment during preg-
nancy on transmission rates or on foetal/neonatal
morbidity, it is extremely unlikely that screening
as presently performed in Switzerland would be
of any benefit. In contrast, such screening is very
likely to be associated with a significant burden of
anxiety and distress among women with suspected
acute toxoplasmosis during pregnancy. Given the
low morbidity and the vertical transmission rate
observed in Switzerland in recent years, the risk
associated with invasive prenatal diagnosis is
 especially likely to outweigh any benefit that may
be expected. 
Still a minor benefit …
Nevertheless, the lack of evidence that treat-
ment during pregnancy would decrease transmis-
sion rates and foetal/neonatal morbidity and mor-
tality also means that a minor benefit cannot be
ruled out with certainty. Hence it is important to
have a surveillance system in order not to miss
major changes when adapting the old strategy. 
A new approach
As shown by studies from Switzerland and
Denmark, combined IgM and IgA screening at
birth serves to identify the vast majority of in-
fected neonates, given 94% sensitivity and 99.9%
specificity [5, 27]. Denmark, with a birth preva-
lence for toxoplasmosis of 2.1 in 10 000 liveborn
neonates, has already published the results of a
nationwide neonatal two-step screening pro-
gramme for congenital toxoplasmosis. In 55 out
of 262 912 newborns (=1/4780) congenital toxo-
plasmosis was confirmed by specific IgG, IgM and
IgA antibodies. Twelve of 47 newborns examined
(=1/21 909) showed clinical signs of infection
such as retinochoroidal lesions or intracranial cal-
cifications. One child had hydrocephalus, in-
tracranial calcifications and retinochoroidal le-
sions. Retinochoroiditis with macular involve-
ment was diagnosed in 9.6% of the eyes at birth
and in 15.6% at one year of age [37]. Thus, new-
born screening in Denmark between 1999 and
2007 did not show that identification and treat-
ment of infected children had any impact on ocu-
lar morbidity, and this led to discontinuation of
this campaign in Denmark in 2007 [29]. In fact
only a single study shows a treatment effect of
cotrimoxazole on recurrence of retinochoroiditis
[37]. Similarly to treatment during pregnancy, no
evidence is available of any benefit from treating
children with congenital toxoplasmosis. Never-
theless, not to treat a symptomatic infection at
birth, for which potentially effective drugs are
available, will probably not be acceptable for care-
givers and paediatricians. Clinical evidence, how-
ever, strongly suggests that symptomatic children
will be identified even without any pregnancy or
neonatal antibody screening due to clinical symp-
toms identified before or after birth. 
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Change of paradigm is reasonable
In the absence of evidence
Lack of available evidence does not mean that
no intervention or treatment has any effect at all,
and hence it appears very difficult to propose
straightforward recommendations. On the other
hand, there are sufficient arguments to put in
question the wild screening system currently
practised in Switzerland and to propose a change
of paradigm regarding congenital toxoplasmosis.
Step 1
Given the low incidence and even lower mor-
bidity of congenital toxoplasmosis, together with
the the fact that any intervention during preg-
nancy presumably has little or no impact but in-
volves significant risks, on the basis of published
evidence it appears that secondary prophylaxis can
in no way be recommended and testing during
pregnancy should therefore be discouraged. 
Step 2
Primary prevention should be strengthened,
by providing women with evidence-based infor-
mation on major sources of toxoplasmosis and
transmission routes of importance. 
Step 3
Finally, to ensure that any possible impact of a
change of paradigm is not overlooked, the surveil-
lance system requires adaptation. 
As a general screening system in neonates
using Guthrie cards appears to be inefficient in
the light of experience in Denmark, the Swiss
Working Group on congenital Toxoplasmosis
proposes to maintain the ongoing surveillance
programmes in the Basel and Lausanne regions. 
Symptomatic children diagnosed with con-
genital toxoplasmosis should still be treated, how-
ever, with a strong recommendation to enroll
them in international studies comparing different
potentially effective drug regimens. 
Symptomatic congenital toxoplasmosis
should again be included in the SPSU surveillance
system. 
7– Publish a consensus/position paper (paedia-
tricians, obstetricians, biologists, public
health) 
– Develop a common national leaflet with re -
commendations on how best to prevent acqui-
sition of toxoplasmosis during pregnancy, and
distribute it to all obstetricians and women
pregnant or planning pregnancy 
– Cease testing for Toxoplasma antibodies be-
fore and during pregnancy – this requires
forceful and intensive promotion of the
change in paradigm among physicians follow-
ing pregnancies or responsible for medical
laboratories
– Maintain and evaluate the ongoing surveil-
lance systems 
– Reactivate SPSU surveillance of symptomatic
congenital toxoplasmosis 
– Treat children with symptomatic congenital
toxoplasmosis – enroll virtually all of these
children in upcoming international treatment
studies
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Recommendations
Thoughts on the practical implementation of this new approach
Clearly, a change in paradigm of this kind
cannot be implemented from one day to the next.
On the day when these new recommendations are
published, many seronegative pregnant women
will be scheduled for follow-up tests. Other preg-
nant women will have started antiparasitic treat-
ment for suspected or proven acute toxoplasmosis
during pregnancy. These women should obviously
not be caused added confusion, and it is certainly
reasonable not to change the approach discussed
and defined earlier. It will also take time to adapt
existing local guidelines to the new recommenda-
tions. The Swiss Working Group on congenital
Toxoplasmosis therefore assumes that nationwide
implementation of the new strategy will take one
or two years until completion.  
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